Drug Development, Health Technology and Public Health

Deliberate AI Announces its Depression and Anxiety Model, AI-COA™, is the First AI/ML Initiative to Be Accepted into the FDA’s ISTAND Pilot Program to Advance Drug Development

Digital Health Global

JANUARY 26, 2024

NEW YORK–(BUSINESS WIRE)– Deliberate AI , a digital health technology company that delivers precision measurement of mental health through AI, today announced its inclusion in the U.S. Food and Drug Administration (FDA) Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.

Drug Development

Drug Development Mental health Psychiatry Digital Health

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

Digital Health Global

NOVEMBER 20, 2023

We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.” Schwartz, A.L, Morris, A.M., Halpern, S.D., N Engl J Med 2023; 388:1252-1254.

Life Science

Life Science Digital Health Drug Development Patient Experience

Connected Health Pulse

Deliberate AI Announces its Depression and Anxiety Model, AI-COA™, is the First AI/ML Initiative to Be Accepted into the FDA’s ISTAND Pilot Program to Advance Drug Development

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

Stay Connected